Please login to the form below

Not currently logged in
Email:
Password:

SMC accepts stem cell mobilization therapy

The Scottish Medicines Consortium has accepted Mozobil for use in NHS Scotland to improve the treatment of blood cancer patients

The Scottish Medicines Consortium's (SMC) decision to accept Mozobil (plerixafor) for use in NHS Scotland has been welcomed by its developers, Genzyme UK. Mozobil is a new stem cell mobilisation therapy aimed at improving results for patients undergoing stem cell transplantation as part of their treatment for the blood cancers, multiple myeloma and lymphoma.

Mozobil is designed to help move stem cells from the bone marrow into the bloodstream and offers hope for patients who might otherwise not be able to generate sufficient stem cells for a successful transplant. Mozobil has been shown to rapidly increase the number of stem cells circulating in the blood.

Eric Low, chief executive of Myeloma UK, said: "Today's decision is very good news for Scottish patients for whom transplantation represents the most effective upfront treatment option. The fact that Mozobil increases the likelihood of collecting enough cells for a transplant is a great breakthrough for the small group of patients who cannot otherwise mobilise enough stem cells. We are delighted the Scottish Medicines Consortium has approved it for use within the NHS in Scotland."

In 2009, Mozobil received marketing authorisation from the European Medicines Agency (EMA) for use in combination with granulocyte-colony stimulating factor to enhance mobilisation of haemopoietic stem cells to the peripheral blood for collection and subsequent transplantation in patients with lymphoma and multiple myeloma whose cells mobilised poorly.

It has already been used in a number of UK hospitals on a named patient basis, for those who had failed to mobilise sufficient stem cells for transplantation using standard treatments.


 

20th January 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics